Chromosome 7 Multiplication in EGFR-positive Lung Carcinomas Based on Tissue Microarray Analysis.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  In Vivo

• Publication date

  2017-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.21873/INVIVO.11106PMID 28652432PMCID PMC5566915
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chromosomes 7/17 multiplication vs true polysomy: a crucial issue in lung and breast EGFR/HER2 dependent carcinoma cases.

  2016cited by this paper
• EGFR gene deregulation mechanisms in lung adenocarcinoma: A molecular review.

  2016cited by this paper
• Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond.

  2015cited by this paper
• Chromosome 7 deregulation in non-small cell lung carcinoma molecular landscape.

  2015cited by this paper
• Glucocorticoid receptor regulates accurate chromosome segregation and is associated with malignancy

  2015cited by this paper
• Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC

  2014cited by this paper
• Therapeutic Strategies Utilized in the Setting of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

  2014cited by this paper
• Increased BRAF copy number in lung adenocarcinoma

  2014cited by this paper
• Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma.

  2014cited by this paper
• Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.

  2014cited by this paper
• Molecular epidemiology of lung cancer and geographic variations with special reference to EGFR mutations.

  2014cited by this paper
• EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation

  2013cited by this paper
• Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.

  2013cited by this paper
• Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor

  2013cited by this paper
• Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors.

  2013cited by this paper
• Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis.

  2010cited by this paper
• Chromosomal and genomic changes in lung cancer

  2010cited by this paper
• Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: Comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study.

  2010cited by this paper
• Evaluation of 7q31 region improves the accuracy of EGFR FISH assay in non small cell lung cancer

  2009cited by this paper
• Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event

  2009cited by this paper
• Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer

  2009cited by this paper
• Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile.

  2009cited by this paper
• The cancer genome

  2009cited by this paper
• Epidermal growth factor receptor immunohistochemistry

  2008cited by this paper
• Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.

  2008cited by this paper
• EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression.

  2008cited by this paper
• First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

  2008cited by this paper
• Lung Cancer Occurrence in Never-Smokers: An Analysis of 13 Cohorts and 22 Cancer Registry Studies

  2008cited by this paper
• Characterizing the cancer genome in lung adenocarcinoma

  2007cited by this paper
• Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma

  2007cited by this paper
• Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry

  2006cited by this paper
• Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma.

  2006cited by this paper
• Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

  2006cited by this paper
• A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter.

  2005cited by this paper
• ERBB receptors and cancer: the complexity of targeted inhibitors

  2005cited by this paper
• Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.

  2005cited by this paper
• ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors

  2005cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay.

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer

  2004cited by this paper
• Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism.

  2003cited by this paper
• Chromosome aberrations in solid tumors

  2003cited by this paper
• Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression.

  2000cited by this paper

• Immunohistochemical detection of cancer genetic abnormalities.

  2024cites this paper
• Pan-cancer Comprehensive Analysis Identified EGFR as a Potential Biomarker for Multiple Tumor Types

  2024cites this paper
• Differences between lung adenocarcinoma and lung squamous cell carcinoma: Driver genes, therapeutic targets, and clinical efficacy

  2024cites this paper
• Escape from Cellular Senescence Is Associated with Chromosomal Instability in Oral Pre-Malignancy

  2023cites this paper
• Investigating the importance of EGFR (− 216G/T), Exo1 (K589E) and LEP (− 2548G/A) gene polymorphisms with risk of lung cancer as potential diagnostic biomarker in Iranian population

  2023influential citation
• Modulation of proliferation factors in lung adenocarcinoma with an analysis of the transcriptional consequences of genomic EGFR activation

  2019cites this paper
• CRISPR/Cas9 Genome Editing of Epidermal Growth Factor Receptor Sufficiently Abolished Oncogenicity in Anaplastic Thyroid Cancer

  2018cites this paper
• Numerical Imbalances of Chromosome 7 in Oral Squamous Cell Carcinoma.

  2018cites this paper
• Predictive Significance of Thymidylate Synthase Expression in Non-small Cell Lung Cancer.

  2017cites this paper